varlitinib (ASLAN001) / ASLAN Pharma 
Welcome,         Profile    Billing    Logout  
 20 Diseases   1 Trial   1 Trial   137 News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
varlitinib (ASLAN001) / ASLAN Pharma
NCT05400915: Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients

Completed
1/2
27
RoW
Variltinib, Paclitaxel
Yonsei University
Gastric Cancer
12/21
06/22
NCT02435927: ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin

Checkmark Pooled analysis from three studies at ASCO GI 2019 [screenshot]
Jan 2019 - Jan 2019: Pooled analysis from three studies at ASCO GI 2019 [screenshot]
Active, not recruiting
1
60
RoW
ASLAN001+ CAPOX (Oxaliplatin, capecitabine), eloxatin, xeloda, ASLAN001 + mFolfox6 (5-FU, leucovorin), 5-Fluorouracil, Folinic acid
National Cancer Centre, Singapore, Aslan Pharmaceuticals, National Medical Research Council (NMRC), Singapore
Solid Tumors
06/21
06/21

Download Options